ProPhase Labs, Inc. Stock price

Equities

PRPH

US74345W1080

Food Processing

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
6.47 USD +3.35% Intraday chart for ProPhase Labs, Inc. +15.12% +43.14%
Sales 2023 45.24M Sales 2024 * 22M Capitalization 117M
Net income 2023 -16M Net income 2024 * -28M EV / Sales 2023 1.8 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 5.31 x
P/E ratio 2023
-4.61 x
P/E ratio 2024 *
-4.17 x
Employees 129
Yield 2023 *
-
Yield 2024 *
-
Free-Float 38.03%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.35%
1 week+15.12%
Current month+44.74%
1 month+36.50%
3 months+43.78%
6 months+48.39%
Current year+43.14%
More quotes
1 week
5.75
Extreme 5.75
6.71
1 month
4.37
Extreme 4.3734
6.71
Current year
4.37
Extreme 4.3734
6.71
1 year
4.05
Extreme 4.05
9.94
3 years
4.05
Extreme 4.05
15.25
5 years
0.00
Extreme 0
16.04
10 years
0.00
Extreme 0
16.04
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 09-06-14
Chief Operating Officer 50 Dec. 31
Comptroller/Controller/Auditor 49 22-06-30
Members of the board TitleAgeSince
Director/Board Member 68 09-05-31
Chief Executive Officer 64 09-06-14
Director/Board Member 44 15-05-31
More insiders
Date Price Change Volume
24-03-28 6.47 +3.35% 16,102
24-03-27 6.26 -0.48% 32,797
24-03-26 6.29 +1.45% 49,364
24-03-25 6.2 +6.16% 49,760
24-03-22 5.84 +3.91% 35,987

Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT

More quotes
ProPhase Labs, Inc. is a diagnostics, genomics and biotech company. The Company leverages its Clinical Laboratory Improvement Amendments (CLIA) lab services to provide whole genome sequencing and research direct to consumers and build a genomics database to be used for further research. It provides traditional CLIA molecular laboratory services, including coronavirus disease (COVID-19) testing. It also operates Pharmaloz, a contract manufacturing subsidiary, which offers the TK Supplements line of dietary supplements, which are distributed in food, drug, and mass stores. The Company's wholly owned subsidiary ProPhase Diagnostics, Inc, offers a broad array of clinical diagnostic and testing services at its CLIA-certified laboratories including polymerase chain reaction (PCR) testing for SARS-CoV-2 (COVID-19) and Influenza A and Influenza B. It also owns the exclusive rights to the BE-Smart Esophageal Pre-Cancer Diagnostic Screening test.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
  1. Stock
  2. Equities
  3. Stock ProPhase Labs, Inc. - Nasdaq